| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accelerating lead development by microwave-enhanced medicinal chemistry
|
Shipe, William D.
|
|
2005
|
|
2 |
p. 155-161
7 p.
|
artikel
|
| 2 |
A critical path approach to advance nanoengineered medical products
|
Sanhai, Wendy R.
|
|
2007
|
|
2 |
p. 35-41
7 p.
|
artikel
|
| 3 |
Advanced behavioural screening: automated home cage ethology
|
Spruijt, Berry M.
|
|
2006
|
|
2 |
p. 231-237
7 p.
|
artikel
|
| 4 |
Advancing women's health via FDA Critical Path Initiative
|
Parekh, A.
|
|
2007
|
|
2 |
p. 69-73
5 p.
|
artikel
|
| 5 |
Affinity separation: divide and conquer the proteome
|
Fang, Xiangming
|
|
2004
|
|
2 |
p. 141-148
8 p.
|
artikel
|
| 6 |
An overview of e-Clinical trials
|
Bunn, Graham
|
|
2006
|
|
2 |
p. 163-166
4 p.
|
artikel
|
| 7 |
Assessment of visual performance in the evaluation of new medical products
|
Drum, B.
|
|
2007
|
|
2 |
p. 55-61
7 p.
|
artikel
|
| 8 |
Blood safety: Opportunities and challenges addressed through Critical Path research at FDA
|
Atreya, Chintamani D.
|
|
2007
|
|
2 |
p. 51-54
4 p.
|
artikel
|
| 9 |
Capillary electrophoresis technologies for screening in drug discovery
|
Wan, Hong
|
|
2005
|
|
2 |
p. 171-178
8 p.
|
artikel
|
| 10 |
Complementary molecular imaging technologies: High resolution SPECT, PET and MRI
|
Meikle, Steven R.
|
|
2006
|
|
2 |
p. 187-194
8 p.
|
artikel
|
| 11 |
Content
|
|
|
2005
|
|
2 |
p. i-
1 p.
|
artikel
|
| 12 |
Contents
|
|
|
2010
|
|
2 |
p. i-
1 p.
|
artikel
|
| 13 |
Contents
|
|
|
2004
|
|
2 |
p. i-
1 p.
|
artikel
|
| 14 |
Contents
|
|
|
2007
|
|
2 |
p. i-
1 p.
|
artikel
|
| 15 |
Current methods for high-throughput detection of novel DNA polymorphisms
|
Peters, Thomas
|
|
2006
|
|
2 |
p. 123-129
7 p.
|
artikel
|
| 16 |
Development and validation of novel imaging technologies to assist translational studies in atherosclerosis
|
Miserus, Robbert-Jan J.H.M.
|
|
2006
|
|
2 |
p. 195-204
10 p.
|
artikel
|
| 17 |
Developments in modulating protein function for effective target validation
|
Ilag, Leodevico L.
|
|
2004
|
|
2 |
p. 113-117
5 p.
|
artikel
|
| 18 |
Drug eluting stents and the critical path initiative: Evolving paradigms for safety evaluation
|
Sanhai, Wendy R.
|
|
2007
|
|
2 |
p. 43-46
4 p.
|
artikel
|
| 19 |
e-Clinical integration strategies
|
Howells, Keith
|
|
2006
|
|
2 |
p. 167-171
5 p.
|
artikel
|
| 20 |
Editorial
|
|
|
2006
|
|
2 |
p. 111-114
4 p.
|
artikel
|
| 21 |
Editorial
|
|
|
2005
|
|
2 |
p. iii-iv
nvt p.
|
artikel
|
| 22 |
Enhanced brain drug delivery: safely crossing the blood–brain barrier
|
Gaillard, Pieter J.
|
|
2012
|
|
2 |
p. e155-e160
nvt p.
|
artikel
|
| 23 |
Enhanced permeability and retention effect for selective targeting of anticancer nanomedicine: are we there yet?
|
Greish, Khaled
|
|
2012
|
|
2 |
p. e161-e166
nvt p.
|
artikel
|
| 24 |
Fall and rise of behavioural pharmacology
|
de Graaf, Joop S.
|
|
2006
|
|
2 |
p. 181-185
5 p.
|
artikel
|
| 25 |
FDA's Critical Path Initiative
|
Woodcock, Janet
|
|
2007
|
|
2 |
p. 33-
1 p.
|
artikel
|
| 26 |
Formulation technologies to overcome poor drug-like properties
|
Alfredson, Tom
|
|
2012
|
|
2 |
p. e71-e72
nvt p.
|
artikel
|
| 27 |
Formulation technologies to overcome unfavorable properties of peptides and proteins for pulmonary delivery
|
Wan, Feng
|
|
2012
|
|
2 |
p. e141-e146
nvt p.
|
artikel
|
| 28 |
From differential gene expression to differential gene function and back
|
Chatterjee-Kishore, Moitreyee
|
|
2004
|
|
2 |
p. 149-156
8 p.
|
artikel
|
| 29 |
From genes to drugs: target validation in Caenorhabditis elegans
|
Sluder, Ann E.
|
|
2004
|
|
2 |
p. 171-177
7 p.
|
artikel
|
| 30 |
Functional genomics and target gene validation in experimental and human disease
|
Schulte, Johannes H.
|
|
2004
|
|
2 |
p. 105-111
7 p.
|
artikel
|
| 31 |
Gene mapping strategies for complex disease and drug response
|
Jawaid, Ansar
|
|
2006
|
|
2 |
p. 131-136
6 p.
|
artikel
|
| 32 |
Genome scale cytometry: High content analysis for high throughput RNAi phenotype profiling
|
Evans, David M.
|
|
2005
|
|
2 |
p. 141-147
7 p.
|
artikel
|
| 33 |
Genotyping technologies for all
|
Ragoussis, Jiannis
|
|
2006
|
|
2 |
p. 115-122
8 p.
|
artikel
|
| 34 |
Global gene expression analysis in the zebrafish: the challenge and the promise
|
Pichler, Franz B.
|
|
2004
|
|
2 |
p. 79-84
6 p.
|
artikel
|
| 35 |
G-protein-coupled receptor screening technologies
|
Greasley, Peter J.
|
|
2005
|
|
2 |
p. 163-170
8 p.
|
artikel
|
| 36 |
Insight of current technologies for oral delivery of proteins and peptides
|
Chin, Jungwook
|
|
2012
|
|
2 |
p. e105-e112
nvt p.
|
artikel
|
| 37 |
Integrative bioinformatics: making sense of the networks
|
Wodak, Shoshana J.
|
|
2004
|
|
2 |
p. 179-187
9 p.
|
artikel
|
| 38 |
Ion channel screening technologies today
|
Terstappen, Georg C.
|
|
2005
|
|
2 |
p. 133-140
8 p.
|
artikel
|
| 39 |
Lipid-based formulations for oral delivery of lipophilic drugs
|
Kuentz, Martin
|
|
2012
|
|
2 |
p. e97-e104
nvt p.
|
artikel
|
| 40 |
Lost in translation? Role of metabolomics in solving translational problems in drug discovery and development
|
van der Greef, Jan
|
|
2006
|
|
2 |
p. 205-211
7 p.
|
artikel
|
| 41 |
Medium-sized molecules – Fertile or futile ground for drug discovery?
|
Zhang, Ming-Qiang
|
|
2010
|
|
2 |
p. e95-e96
nvt p.
|
artikel
|
| 42 |
Methods for the synthesis of macrocycle libraries for drug discovery
|
Terrett, Nicholas K.
|
|
2010
|
|
2 |
p. e97-e104
nvt p.
|
artikel
|
| 43 |
Microarrays meet the Voltaire challenge: Drug discovery on a chip?
|
Jackson, David B.
|
|
2006
|
|
2 |
p. 153-161
9 p.
|
artikel
|
| 44 |
Multiplexed high content screening assays create a systems cell biology approach to drug discovery
|
Taylor, D. Lansing
|
|
2005
|
|
2 |
p. 149-154
6 p.
|
artikel
|
| 45 |
Mycobacterial genetics in target validation
|
Warner, Digby F.
|
|
2004
|
|
2 |
p. 93-98
6 p.
|
artikel
|
| 46 |
Nanobodies – from llamas to therapeutic proteins
|
Kolkman, Joost A.
|
|
2010
|
|
2 |
p. e139-e146
nvt p.
|
artikel
|
| 47 |
Optimizing the physical form – opportunities and limitations
|
Byrn, Stephen R.
|
|
2012
|
|
2 |
p. e73-e78
nvt p.
|
artikel
|
| 48 |
Overcoming poor oral bioavailability using nanoparticle formulations – opportunities and limitations
|
Desai, Preshita P.
|
|
2012
|
|
2 |
p. e87-e95
nvt p.
|
artikel
|
| 49 |
Overcoming poor permeability – the role of prodrugs for oral drug delivery
|
Maag, Hans
|
|
2012
|
|
2 |
p. e121-e130
nvt p.
|
artikel
|
| 50 |
Overcoming poor permeability: translating permeation enhancers for oral peptide delivery
|
Maher, Sam
|
|
2012
|
|
2 |
p. e113-e119
nvt p.
|
artikel
|
| 51 |
Overview and comparison of ortholog databases
|
Alexeyenko, Andrey
|
|
2006
|
|
2 |
p. 137-143
7 p.
|
artikel
|
| 52 |
Peptide and protein transdermal drug delivery
|
Herwadkar, Anushree
|
|
2012
|
|
2 |
p. e147-e154
nvt p.
|
artikel
|
| 53 |
Peptide scalpels for site-specific dissection of the DNA–protein interface
|
Verzele, Dieter
|
|
2010
|
|
2 |
p. e115-e123
nvt p.
|
artikel
|
| 54 |
Potential and limitations of genetic manipulation in animals
|
O'Sullivan, Gerard J.
|
|
2006
|
|
2 |
p. 173-180
8 p.
|
artikel
|
| 55 |
Preclinical in vitro screening assays for drug-like properties
|
Li, Albert P.
|
|
2005
|
|
2 |
p. 179-185
7 p.
|
artikel
|
| 56 |
Prediction and classification of protein functions
|
Ruepp, Andreas
|
|
2006
|
|
2 |
p. 145-151
7 p.
|
artikel
|
| 57 |
Prediction of failure load using micro-finite element analysis models: Toward in vivo strength assessment
|
van Lenthe, G. Harry
|
|
2006
|
|
2 |
p. 221-229
9 p.
|
artikel
|
| 58 |
Proteomic technologies for cancer target validation
|
Jain, K.K.
|
|
2004
|
|
2 |
p. 75-78
4 p.
|
artikel
|
| 59 |
Recombinant approaches to large polyketide molecules as potential drugs
|
Peirú, Salvador
|
|
2010
|
|
2 |
p. e105-e113
nvt p.
|
artikel
|
| 60 |
Reverse pharmacology and the de-orphanization of 7TM receptors
|
Kotarsky, Knut
|
|
2004
|
|
2 |
p. 99-104
6 p.
|
artikel
|
| 61 |
RNA interference as a tool for target validation
|
Pauls, Eduardo
|
|
2004
|
|
2 |
p. 135-140
6 p.
|
artikel
|
| 62 |
siRNA as a conventional drug in the clinic? Challenges and current technologies
|
Shim, Min Suk
|
|
2012
|
|
2 |
p. e167-e173
nvt p.
|
artikel
|
| 63 |
siRNAs as potential drugs
|
Wang, Xiaoxia
|
|
2010
|
|
2 |
p. e125-e130
nvt p.
|
artikel
|
| 64 |
Smart polymers for peptide and protein parenteral sustained delivery
|
Oak, Mayura
|
|
2012
|
|
2 |
p. e131-e140
nvt p.
|
artikel
|
| 65 |
Synthetic host molecules and sequestrants as therapeutic agents
|
Zhang, Ming-Qiang
|
|
2010
|
|
2 |
p. e131-e137
nvt p.
|
artikel
|
| 66 |
Tapping, pulling, probing: atomic force microscopy in drug discovery
|
Legleiter, Justin
|
|
2004
|
|
2 |
p. 163-169
7 p.
|
artikel
|
| 67 |
The innovative use of a large-scale industry biomedical consortium to research the genetic basis of drug induced serious adverse events
|
Holden, Arthur L.
|
|
2007
|
|
2 |
p. 75-87
13 p.
|
artikel
|
| 68 |
The pharmacology of electrical stimulation in the heart: Where devices meet drugs
|
Krauthamer, Victor
|
|
2007
|
|
2 |
p. 63-67
5 p.
|
artikel
|
| 69 |
The Predictive Safety Testing Consortium: A synthesis of the goals, challenges and accomplishments of the Critical Path
|
Goodsaid, Federico M.
|
|
2007
|
|
2 |
p. 47-50
4 p.
|
artikel
|
| 70 |
The role of bioinformatics in target validation
|
Whittaker, Paul A.
|
|
2004
|
|
2 |
p. 125-133
9 p.
|
artikel
|
| 71 |
The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate
|
Van den Mooter, Guy
|
|
2012
|
|
2 |
p. e79-e85
nvt p.
|
artikel
|
| 72 |
The use of micro-CT to study bone architecture dynamics noninvasively
|
van der Linden, Jacqueline C.
|
|
2006
|
|
2 |
p. 213-219
7 p.
|
artikel
|
| 73 |
The use of nucleic acid tools for target validation in central nervous system therapy
|
Godfray, Jenny
|
|
2004
|
|
2 |
p. 85-91
7 p.
|
artikel
|
| 74 |
Use of ribozymes in validation of targets involved in tumor progression
|
Zaffaroni, Nadia
|
|
2004
|
|
2 |
p. 119-124
6 p.
|
artikel
|
| 75 |
Yeast as a budding technology in target validation
|
Bays, Nathan
|
|
2004
|
|
2 |
p. 157-162
6 p.
|
artikel
|
| 76 |
Yeast as a screening tool
|
Barberis, Alcide
|
|
2005
|
|
2 |
p. 187-192
6 p.
|
artikel
|
Tijdschrift beschrijving